Science and Technology Science and Technology
Thu, August 20, 2009
Wed, August 19, 2009
Tue, August 18, 2009

Accelrys: Dr. Frank Brown of Accelrys Named to Board of Directors of BioIT Alliance


Published on 2009-08-18 07:10:37, Last Modified on 2009-08-18 07:10:45 - Market Wire
  Print publication without navigation


SAN DIEGO, CA--(Marketwire - August 18, 2009) - Accelrys, Inc. (NASDAQ: [ ACCL ]), a leading provider of scientific business intelligence software and services, today announced that Dr. Frank Brown, senior vice president and chief science officer of Accelrys, has been appointed to the board of directors of the [ BioIT Alliance ], a group of organizations working together to realize the potential of personalized medicine. Accelrys is one of the founding members of the alliance.

Appointed by the BioIT Alliance, Dr. Brown will join an elite group of industry leaders in his new position.

"The appointment of Dr. Brown to the BioIT Alliance board of directors is due to his passion for scientific informatics and addressing the challenges that life sciences companies face in the areas of research, discovery and development," said Les Jordan, director of the BioIT Alliance and industry technology strategist for Life Sciences at Microsoft. "He will undoubtedly bring strong, reasoned leadership to this new role, and his guidance will help lead the BioIT Alliance further in its mission to drive integration between technologies, develop standards and foster collaboration."

The BioIT Alliance unites the healthcare IT, pharmaceutical, biotech, hardware and software industries to explore new ways to share complex biomedical data and collaborate among multi-disciplinary teams to speed the pace of discovery. Life Science companies have unique technical challenges in data integration, collaboration, and knowledge management that cannot be solved by any organization alone. The BioIT Alliance brings together science, health and technology leaders to consider innovative ways to address these challenges and use technology to reduce costs, streamline research, and market their products more effectively.

"I'm delighted to be appointed to the BioIT Alliance board. This is an exciting opportunity to help lead conversations about some of the most important issues confronting the life sciences industry," said Brown. "If personalized medicine is to become a reality, it is more important than ever to deliver information technologies which increase the success rate of discovering and developing New Chemical Entities (NCEs) and to design strategies for the most effective application of these NCEs to the health care system."

About BioIT Alliance

Formed in 2006, the BioIT Alliance is a cross-industry group working to integrate science and technology in order to accelerate the pace of drug discovery and realize the potential of personalized medicine. Founding members include Accelrys Software Inc., Affymetrix, Inc., Agilent Technologies Inc., Amylin Pharmaceuticals, Inc., Applied Biosystems, The BioTeam Inc., Digipede Technologies LLC, Discovery Biosciences Corporation, Geospiza Inc., Hewlett-Packard Development Company, L.P., Illumina Inc., InterKnowlogy, Microsoft Corporation, Sun Microsystems Inc., The Scripps Research Institute, VizX Labs LLC and other key companies in the pharmaceutical, biotech, hardware and software industries. Additional information about the BioIT Alliance can be found on the BioIT Alliance Web site at [ http://www.bioitalliance.org ]

About Accelrys, Inc.

Headquartered in San Diego, California, Accelrys [ develops scientific business intelligence ] software and solutions for the life sciences, energy, chemicals, aerospace, and consumer products [ industries ]. [ Customers ] include many Fortune 500 companies and other commercial entities, as well as academic and government entities. Accelrys has a vast portfolio of computer-aided design modeling and simulation offerings which assist customers in conducting scientific experiments 'in silico' in order to reduce the duration and cost of discovering and developing new drugs and materials. Its [ scientific business intelligence platform ] underlies the company's computer-aided design modeling and simulation offerings. The Accelrys platform can be used with both Accelrys and competitive products, as well as with customers' proprietary predictive science products. Its flexibility, ease-of-use and advanced chemical, text and image analysis and reporting capabilities enable customers to mine, aggregate, analyze and report scientific data from disparate sources, thereby better utilizing scientific data within their organizations. For more information about Accelrys, visit [ http://accelrys.com/ ]

Contributing Sources